

Patient Square Capital Appoints Health Care Veteran Colin Shannon as Senior Advisor



Patient Square Capital announced that Colin Shannon has joined as a Senior Advisor. Mr. Shannon was most recently Chairman and Chief Executive Officer at global contract research organization PRA Health Sciences (formerly PRA International). During Mr. Shannon's time as CEO of PRA Health Sciences, revenue of the company grew over seven-fold from less than \$460mm to over \$3.3 billion.

"Colin is one of the most talented executives with whom I have ever worked, and I am personally thrilled to be working with him again," said Jim Momtazee, Managing Partner of Patient Square. "His proven track record as an operator, talent developer and strategic thinker at hugely successful health care organizations will bring an important additional perspective in our assessment of new investment opportunities and in creating value in the companies in which we invest."

"I am a huge believer in Patient Square's approach to partnering with innovative companies that will have a meaningful impact and improve the lives of patients," said Mr. Shannon. "I look forward to collaborating with the team to support their efforts to invest and grow companies."

Prior to PRA Health Sciences, Mr. Shannon was at Pharmaceutical Product Development Inc. (PPD), where he held various executive roles, including Executive Vice President of Global Clinical Operations. Other key positions included Chief Operating Officer for European operations, Vice President and Chief Financial and Administrative Officer for International Operations, and Executive Director and Chief Financial Officer for Europe. Before PPD, Mr. Shannon spent over 15 years in the utility and multimedia industries, focusing on financial and accounting capabilities. Mr. Shannon holds a M.B.A. from City University in London and is a Fellow Member of the Chartered Association of Accountants. Mr. Shannon currently serves on the Board of Directors of Icon PLC.

Source: Patient Square Capital
Published on: Tue, 26 Jul 2022